AbCellera's Q1 Revenue More Than Doubles, Crushing Estimates
ABCL has more than doubled off its 52-week low of $1.94 on elevated volume (2.5× avg).
Summary
AbCellera Biologics reported Q1 revenue of $8.30 million, which more than doubled year-over-year and significantly surpassed analyst consensus estimates of $5.86 million. The company also posted a narrower net loss compared to Q1 2025, driven by lower SG&A expenses, and ended the quarter with $655 million in available liquidity. This strong revenue growth and beat, coupled with improved profitability, indicates positive operational momentum and effective cost management. This is new, material information for traders, distinct from the 2025 full-year results reported in the February 10-K. Investors will now focus on the company's stated plans to deliver data readouts for clinical programs and advance key candidates into IND-enabling studies in 2026.
At the time of this announcement, ABCL was trading at $5.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $1.94 to $6.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.